Is BEAM undervalued or overvalued?

As of 2025-03-20, the Intrinsic Value of Beam Therapeutics Inc (BEAM) is 673.70 USD. This BEAM valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 23.64 USD, the upside of Beam Therapeutics Inc is 2,749.80%. This means that BEAM is undervalued by 2,749.80%.

The range of the Intrinsic Value is 647.47 - 700.96 USD

	Range	Selected	Upside
a
DCF (Growth 5y)	(2,433.22) - (1,121.24)	(1,501.67)	-6452.3%
DCF (Growth 10y)	(882.03) - (1,662.06)	(1,110.27)	-4796.6%
DCF (EBITDA 5y)	647.47 - 700.96	673.70	2749.8%
DCF (EBITDA 10y)	773.74 - 913.56	841.18	3458.3%
Fair Value	-22.51 - -22.51	-22.51	-195.21%
P/E	(142.16) - (218.87)	(171.51)	-825.5%
EV/EBITDA	(54.72) - 931.36	322.32	1263.5%
EPV	(42.18) - (50.40)	(46.29)	-295.8%
DDM - Stable	(43.70) - (142.13)	(92.92)	-493.1%
DDM - Multi	(59.58) - (153.19)	(86.10)	-464.2%